Dr. Strauss on Mitigating Oral Mucositis Symptoms
William Strauss, MD, Executive Director, Medical Affairs, AMAG Pharmaceuticals, Inc., discusses a study that analyzed mitigating oral mucositis symptoms in patients with head and neck cancers being treated with chemoradiation therapy.
William Strauss, MD, Executive Director, Medical Affairs, AMAG Pharmaceuticals, Inc., discusses a study that analyzed mitigating oral mucositis symptoms in patients with head and neck cancers being treated with chemoradiation therapy.
The study enrolled 120 patients with head and neck cancers who were scheduled to receive a combination of chemotherapy and radiation therapy. Patients were randomized to receive MuGard, an oral mucoadhesive hydrogel considered a device by the FDA, or a saline-bicarbonate rinse.
The patients received 5-10cc of MuGard 6 times daily or the control rinse of saline-bicarbonate​. Saline-bicarbonate rinse was labeled as a sham because it is currently recommended by the NCI, though there is debate over its efficacy.
